HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study.

Rainer Weber; Caroline Sabin; Peter Reiss; Stephane de Wit; Signe W Worm; Matthew Law; Francois Dabis; Antonella D'Arminio Monforte; Eric Fontas; Wafaa El-Sadr; Ole Kirk; Martin Rickenbach; Andrew Phillips; Bruno Ledergerber; Jens Lundgren; Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group

doi:10.3851/imp1681

HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study.

Rainer Weber, Caroline Sabin, Peter Reiss, Stephane de Wit, Signe W Worm, Matthew Law, Francois Dabis, Antonella D'Arminio Monforte, Eric Fontas, Wafaa El-Sadr, Ole Kirk, Martin Rickenbach, Andrew Phillips, Bruno Ledergerber, Jens Lundgren, Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group

Department of Immunology and Microbiology

29 Citations (Scopus)

Abstract

Background: Data on a link between HCV or HBV infection and the development of cardiovascular disease among HIV-negative and HIV-positive individuals are conflicting. We sought to investigate the association between HBV or HCV infection and myocardial infarction in HIV-infected individuals. Methods: The prospective observational database of the D:A:D collaboration of 11 cohorts of HIV-infected individuals, including 212 clinics in Europe, the United States and Australia was used. Multivariate Poisson regression was used to assess the effect of HCV or HBV infection on the development of myocardial infarction after adjustment for potential confounders, including cardiovascular risk factors, diabetes mellitus and exposure to antiretroviral therapy. Results: Of 33,347 individuals, 517 developed a myocardial infarction over 157,912 person-years, with an event rate of 3.3 events/1,000 person-years (95% confidence interval [CI] 3.0-3.6). Event rates (95% CIs) per 1,000 person-years in those who were HCV- seronegative and HCV-seropositive were 3.3 (3.0-3.7) and 2.7 (2.2-3.3), respectively, and for those who were HBV-seronegative, had inactive infection or had active infection were 3.2 (2.8-3.5), 4.2 (3.1-5.2) and 2.8 (1.8-3.9), respectively. After adjustment, there was no association between HCV seropositivity (rate ratio 0.86 [95% CI 0.62-1.19]), inactive HBV infection (rate ratio 1.07 [95% CI 0.79-1.43]) or active HBV infection (rate ratio 0.78 [95% CI 0.52-1.15]) and the development of myocardial infarction. Conclusions: We found no association between HBV or HCV coinfection and the development of myocardial infarction among HIV-infected individuals.

Original language	English
Journal	Antiviral Therapy
Volume	15
Issue number	8
Pages (from-to)	1077-86
Number of pages	10
ISSN	1359-6535
DOIs	https://doi.org/10.3851/imp1681
Publication status	Published - 1 Jan 2010

Keywords

Adult
Australia
Cohort Studies
Europe
Female
HIV Infections
Hepatitis B
Hepatitis B Antibodies
Hepatitis C
Hepatitis C Antibodies
Humans
Male
Multivariate Analysis
Myocardial Infarction
Poisson Distribution
Prospective Studies
Regression Analysis
Risk Factors
Stroke
Substance Abuse, Intravenous
Time Factors
United States

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3851/imp1681

https://journals.sagepub.com/doi/pdf/10.3851/IMP1681

Cite this

Weber, R., Sabin, C., Reiss, P., de Wit, S., Worm, S. W., Law, M., Dabis, F., D'Arminio Monforte, A., Fontas, E., El-Sadr, W., Kirk, O., Rickenbach, M., Phillips, A., Ledergerber, B., Lundgren, J., & Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group (2010). HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. Antiviral Therapy, 15(8), 1077-86. https://doi.org/10.3851/imp1681

Weber, R, Sabin, C, Reiss, P, de Wit, S, Worm, SW, Law, M, Dabis, F, D'Arminio Monforte, A, Fontas, E, El-Sadr, W, Kirk, O, Rickenbach, M, Phillips, A, Ledergerber, B, Lundgren, J & Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group 2010, 'HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study.', Antiviral Therapy, vol. 15, no. 8, pp. 1077-86. https://doi.org/10.3851/imp1681

@article{beadf73c86cf455e8419e7b82d69db84,

title = "HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study.",

abstract = "Background: Data on a link between HCV or HBV infection and the development of cardiovascular disease among HIV-negative and HIV-positive individuals are conflicting. We sought to investigate the association between HBV or HCV infection and myocardial infarction in HIV-infected individuals. Methods: The prospective observational database of the D:A:D collaboration of 11 cohorts of HIV-infected individuals, including 212 clinics in Europe, the United States and Australia was used. Multivariate Poisson regression was used to assess the effect of HCV or HBV infection on the development of myocardial infarction after adjustment for potential confounders, including cardiovascular risk factors, diabetes mellitus and exposure to antiretroviral therapy. Results: Of 33,347 individuals, 517 developed a myocardial infarction over 157,912 person-years, with an event rate of 3.3 events/1,000 person-years (95% confidence interval [CI] 3.0-3.6). Event rates (95% CIs) per 1,000 person-years in those who were HCV- seronegative and HCV-seropositive were 3.3 (3.0-3.7) and 2.7 (2.2-3.3), respectively, and for those who were HBV-seronegative, had inactive infection or had active infection were 3.2 (2.8-3.5), 4.2 (3.1-5.2) and 2.8 (1.8-3.9), respectively. After adjustment, there was no association between HCV seropositivity (rate ratio 0.86 [95% CI 0.62-1.19]), inactive HBV infection (rate ratio 1.07 [95% CI 0.79-1.43]) or active HBV infection (rate ratio 0.78 [95% CI 0.52-1.15]) and the development of myocardial infarction. Conclusions: We found no association between HBV or HCV coinfection and the development of myocardial infarction among HIV-infected individuals.",

keywords = "Adult, Australia, Cohort Studies, Europe, Female, HIV Infections, Hepatitis B, Hepatitis B Antibodies, Hepatitis C, Hepatitis C Antibodies, Humans, Male, Multivariate Analysis, Myocardial Infarction, Poisson Distribution, Prospective Studies, Regression Analysis, Risk Factors, Stroke, Substance Abuse, Intravenous, Time Factors, United States",

author = "Rainer Weber and Caroline Sabin and Peter Reiss and {de Wit}, Stephane and Worm, {Signe W} and Matthew Law and Francois Dabis and {D'Arminio Monforte}, Antonella and Eric Fontas and Wafaa El-Sadr and Ole Kirk and Martin Rickenbach and Andrew Phillips and Bruno Ledergerber and Jens Lundgren and {Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group}",

year = "2010",

month = jan,

day = "1",

doi = "10.3851/imp1681",

language = "English",

volume = "15",

pages = "1077--86",

journal = "Antiviral Therapy",

issn = "1359-6535",

publisher = "International Medical Press",

number = "8",

}

TY - JOUR

T1 - HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study.

AU - Weber, Rainer

AU - Sabin, Caroline

AU - Reiss, Peter

AU - de Wit, Stephane

AU - Worm, Signe W

AU - Law, Matthew

AU - Dabis, Francois

AU - D'Arminio Monforte, Antonella

AU - Fontas, Eric

AU - El-Sadr, Wafaa

AU - Kirk, Ole

AU - Rickenbach, Martin

AU - Phillips, Andrew

AU - Ledergerber, Bruno

AU - Lundgren, Jens

AU - Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Background: Data on a link between HCV or HBV infection and the development of cardiovascular disease among HIV-negative and HIV-positive individuals are conflicting. We sought to investigate the association between HBV or HCV infection and myocardial infarction in HIV-infected individuals. Methods: The prospective observational database of the D:A:D collaboration of 11 cohorts of HIV-infected individuals, including 212 clinics in Europe, the United States and Australia was used. Multivariate Poisson regression was used to assess the effect of HCV or HBV infection on the development of myocardial infarction after adjustment for potential confounders, including cardiovascular risk factors, diabetes mellitus and exposure to antiretroviral therapy. Results: Of 33,347 individuals, 517 developed a myocardial infarction over 157,912 person-years, with an event rate of 3.3 events/1,000 person-years (95% confidence interval [CI] 3.0-3.6). Event rates (95% CIs) per 1,000 person-years in those who were HCV- seronegative and HCV-seropositive were 3.3 (3.0-3.7) and 2.7 (2.2-3.3), respectively, and for those who were HBV-seronegative, had inactive infection or had active infection were 3.2 (2.8-3.5), 4.2 (3.1-5.2) and 2.8 (1.8-3.9), respectively. After adjustment, there was no association between HCV seropositivity (rate ratio 0.86 [95% CI 0.62-1.19]), inactive HBV infection (rate ratio 1.07 [95% CI 0.79-1.43]) or active HBV infection (rate ratio 0.78 [95% CI 0.52-1.15]) and the development of myocardial infarction. Conclusions: We found no association between HBV or HCV coinfection and the development of myocardial infarction among HIV-infected individuals.

AB - Background: Data on a link between HCV or HBV infection and the development of cardiovascular disease among HIV-negative and HIV-positive individuals are conflicting. We sought to investigate the association between HBV or HCV infection and myocardial infarction in HIV-infected individuals. Methods: The prospective observational database of the D:A:D collaboration of 11 cohorts of HIV-infected individuals, including 212 clinics in Europe, the United States and Australia was used. Multivariate Poisson regression was used to assess the effect of HCV or HBV infection on the development of myocardial infarction after adjustment for potential confounders, including cardiovascular risk factors, diabetes mellitus and exposure to antiretroviral therapy. Results: Of 33,347 individuals, 517 developed a myocardial infarction over 157,912 person-years, with an event rate of 3.3 events/1,000 person-years (95% confidence interval [CI] 3.0-3.6). Event rates (95% CIs) per 1,000 person-years in those who were HCV- seronegative and HCV-seropositive were 3.3 (3.0-3.7) and 2.7 (2.2-3.3), respectively, and for those who were HBV-seronegative, had inactive infection or had active infection were 3.2 (2.8-3.5), 4.2 (3.1-5.2) and 2.8 (1.8-3.9), respectively. After adjustment, there was no association between HCV seropositivity (rate ratio 0.86 [95% CI 0.62-1.19]), inactive HBV infection (rate ratio 1.07 [95% CI 0.79-1.43]) or active HBV infection (rate ratio 0.78 [95% CI 0.52-1.15]) and the development of myocardial infarction. Conclusions: We found no association between HBV or HCV coinfection and the development of myocardial infarction among HIV-infected individuals.

KW - Adult

KW - Australia

KW - Cohort Studies

KW - Europe

KW - Female

KW - HIV Infections

KW - Hepatitis B

KW - Hepatitis B Antibodies

KW - Hepatitis C

KW - Hepatitis C Antibodies

KW - Humans

KW - Male

KW - Multivariate Analysis

KW - Myocardial Infarction

KW - Poisson Distribution

KW - Prospective Studies

KW - Regression Analysis

KW - Risk Factors

KW - Stroke

KW - Substance Abuse, Intravenous

KW - Time Factors

KW - United States

U2 - 10.3851/imp1681

DO - 10.3851/imp1681

M3 - Journal article

C2 - 21149914

SN - 1359-6535

VL - 15

SP - 1077

EP - 1086

JO - Antiviral Therapy

JF - Antiviral Therapy

IS - 8

ER -

HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study.

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this